SCHEMBL2007007

SCHEMBL2007007

COc1cc(CCCO)cc(OC)c1OC

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNKS2 Q9H2K2 1/20 0.68
TUBB1 Q9H4B7 5/20 0.60
TUBB4A P04350 4/20 0.60
TUBB P07437 4/20 0.60
TUBA3C P0DPH7 4/20 0.60
TUBA1B P68363 4/20 0.60
TUBA4A P68366 4/20 0.60
TUBB4B P68371 4/20 0.60
TUBB3 Q13509 4/20 0.60
TUBB2A Q13885 4/20 0.60
TUBB8 Q3ZCM7 4/20 0.60
TUBA3E Q6PEY2 4/20 0.60
TUBA1A Q71U36 4/20 0.60
TUBA1C Q9BQE3 4/20 0.60
TUBB6 Q9BUF5 4/20 0.60
TUBB2B Q9BVA1 4/20 0.60
HTR2A P28223 1/20 0.60
HTR2C P28335 1/20 0.60
HTR2B P41595 1/20 0.60
PTGS2 P35354 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23266383 0.94 TUBB1 (0.63) TNKS2TUBB1TUBB4ATUBBTUBA3C
SCHEMBL4740186 0.92 TUBB4A (0.61) TNKS2TUBB1TUBB4ATUBBTUBA3C
SCHEMBL20376310 0.89 TNKS2 (0.60) TNKS2TUBB1TUBB4ATUBBTUBA3C
SCHEMBL5833688 0.88 HTR2A (0.64) TNKS2TUBB1TUBB4ATUBBTUBA3C
SCHEMBL7424861 0.87 HTR2A (0.69) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL22609994 0.87 TNKS2 (0.62) TNKS2TUBB1TUBB4ATUBBTUBA3C
SCHEMBL27570422 0.86 TNKS2 (0.53) TNKS2TUBB1TUBB4ATUBBTUBA3C
SCHEMBL8772722 0.84 TNKS2 (0.51) TNKS2TUBB1TUBB4ATUBBTUBA3C
SCHEMBL2914283 0.84 TNKS2 (0.86) TNKS2TUBB1TUBB4ATUBBTUBA3C
SCHEMBL4042724 0.84 TNKS2 (0.58) TNKS2TUBB1TUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327878-A1 PSEUDOMONAS PUTIDA STRAINS ENGINEERED FOR PRODUCTION OF MUCONIC ACID FROM P-METHOXYLATED BENZOIC ACIDS Alliance for Energy Innovation, LLC 2024-10-03 US disclosed
EP-3746440-B1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME UNIV TEXAS (US) 2023-07-05 EP disclosed
EP-3746440-B1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME UNIV TEXAS (US) 2023-07-05 EP disclosed
US-11345659-B2 Pipecolic esters for inhibition of the proteasome BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-05-31 US disclosed
US-11345659-B2 Pipecolic esters for inhibition of the proteasome BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2022-05-31 US disclosed
US-20210002220-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2021-01-07 US disclosed
US-20210002220-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY 2021-01-07 US disclosed
EP-3746440-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME Board of Regents, The University of Texas System (US) 2020-12-09 EP disclosed
EP-3007696-B1 NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF UNIV TEXAS (US) 2019-10-16 EP disclosed
EP-3007696-B1 NOVEL ALLOSTERIC INHIBITORS OF PROTEASOME AND METHODS OF USE THEREOF UNIV TEXAS (US) 2019-10-16 EP disclosed
US-5795908-A FKBP IMMUNOPHILINS FOR ENZYME INHIBITORS GPI NIL HOLDINGS, INC. (US) 1998-08-18 US disclosed
EP-0801071-A1 LEWIS X DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1997-10-15 EP disclosed
EP-0769006-A4 GUILFORD PHARM INC (US) 1997-05-28 EP disclosed
EP-0769006-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1997-04-23 EP disclosed
US-5614547-A Small molecule inhibitors of rotamase enzyme GUILFORD PHARMACEUTICALS INC. (US) 1997-03-25 US disclosed
WO-1996040633-A9 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY 1997-02-27 WO disclosed
WO-1996040633-A1 SMALL MOLECULE INHIBITORS OF ROTAMASE ENZYME ACTIVITY GUILFORD PHARMACEUTICALS INC. (US) 1996-12-19 WO disclosed
US-5321135-A Process for the preparation of polycyclic compounds using ferric perchlorate and acid trifluoroacidic TSUMURA & CO. (JP) 1994-06-14 US disclosed
EP-0594890-A1 Polycyclic compounds, their preparation and their use as phosphodiesterases inhibitors TSUMURA & CO. (JP) 1994-05-04 EP disclosed
EP-0511666-A1 Process for the preparation of polycyclic compounds TSUMURA & CO. (JP) 1992-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11345659-B2 Pipecolic esters for inhibition of the proteasome PSMG3, PSME3, PSMC1 TNKS2 1320/4885TUBB1 723/4885TUBB4A 1159/4885
US-20210002220-A1 PIPECOLIC ESTERS FOR INHIBITION OF THE PROTEASOME PSMG3, PSME3, PSMC1 TNKS2 1320/4885TUBB1 723/4885TUBB4A 1159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.